Nuvation Bio (NYSE: NUVB) posts $31.7M Q2 revenue and $62.8M loss
Nuvation Bio (NYSE: NUVB) announced Q2 2026 revenue of $31.7 million, driven by strong sales of its ROS1 inhibitor IBTROZI and collaboration agreements, representing a significant increase from the previous year. Despite the revenue growth, the company reported a net loss of $62.8 million due to high research and development and administrative expenses. Nuvation Bio also provided updates on its clinical pipeline, including positive Phase 2 data for safusidenib and strategic financial moves to strengthen its balance sheet.
Nuvation Bio (NUVB) Corporate presentation Summary
Nuvation Bio (NUVB) presented a corporate summary highlighting its focus on oncology medicines and strong financial position. The company emphasized the success of IBTROZI (taletrectinib), approved for advanced ROS1+ NSCLC, noting its high efficacy, favorable safety profile, and significant market potential. The presentation also touched upon a robust pipeline and accelerating adoption of first-line oncology drugs.
Nuvation Bio (NUVB) raises $287.5M in 0.75% convertible notes with greenshoe
Nuvation Bio Inc. has successfully closed a registered underwritten offering, raising $287.5 million through 0.75% Convertible Senior Notes due 2032, which included a $37.5 million greenshoe option exercised by underwriters. The company expects net proceeds of approximately $277.6 million, with a portion used for capped call transactions to mitigate dilution. The remaining funds are allocated for general corporate purposes, including working capital and operating expenses.
Nuvation Bio Inc. Class A (NUVB) Stock Price | Live Quotes & Charts | NYSE
This page provides live quotes and charts for Nuvation Bio Inc. Class A (NUVB) stock, showing its current price of $6.11, an increase of $0.24 (4.09%). It indicates that analyst ratings and earnings information for NUVB are not currently available. The page also includes disclaimers about the risks of stock trading and statistics suggesting that most day traders lose money.
Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering
Nuvation Bio Inc. announced that the underwriters have fully exercised their over-allotment option, or "Greenshoe Exercise," to purchase an additional $37.5 million of its 0.75% Convertible Senior Notes due 2032. This brings the total offering to $287.5 million. The net proceeds, estimated at $277.6 million, will be used for general corporate purposes, including working capital and operational expenses, after covering the cost of additional capped call transactions.
Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering
Nuvation Bio Inc. announced the full exercise of its underwriters' over-allotment option (Greenshoe Exercise) to purchase an additional $37.5 million in 0.75% Convertible Senior Notes due 2032, bringing the total offering to $287.5 million. The net proceeds of approximately $277.6 million, after deductions, will be used to cover the cost of additional capped call transactions and for general corporate purposes. This offering was conducted following a registration statement filed with the SEC.
Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering
Nuvation Bio Inc. announced that the underwriters have fully exercised their over-allotment option, or "Greenshoe Exercise," to purchase an additional $37.5 million in convertible senior notes due 2032. This brings the total aggregate principal amount of notes sold in the offering to $287.5 million. The net proceeds from the offering are estimated at approximately $277.6 million, which will be used for general corporate purposes and to cover the cost of additional capped call transactions.
Total common shares outstanding of Nuvation Bio, Inc. Class A – FWB:1E30
This article provides details on the total common shares outstanding for Nuvation Bio, Inc. Class A, traded on the Frankfurt Stock Exchange under the ticker FWB:1E30. It indicates that the market was closed with no trades when the information was accessed. The page also features an overview for this specific stock, noting its category under biotechnology within health technology.
Price to earnings forward of Nuvation Bio, Inc. Class A – FWB:1E30
This article provides financial information for Nuvation Bio, Inc. Class A (FWB:1E30) on the Frankfurt Stock Exchange. It specifically highlights the "Price to earnings forward" metric for the company. The page appears to be a financial data presentation without detailed analysis.
ETFs Investing in Nuvation Bio, Inc. Class A Stocks
This article lists various Exchange Traded Funds (ETFs) that hold Nuvation Bio, Inc. Class A stocks, providing details such as market value, weight, issuer, management style, expense ratio, AUM, price, and 3-year NAV total return. The ETFs cover different investment focuses including small-cap, health care, biotechnology, micro-cap, and ESG, offering diverse options for investors interested in Nuvation Bio.
Nuvation Bio Issues Convertible Notes, Retires Secured Debt
Nuvation Bio (NUVB) recently completed a public offering of $250 million in 0.75% Convertible Senior Notes due 2032, allowing the company to retire approximately $58.5 million of existing secured debt. This move reshapes Nuvation Bio's capital structure, replacing secured debt with longer-dated convertible notes, which could ease short-term balance sheet pressure but introduces potential future equity dilution risk for shareholders. Analysts have a "Buy" rating on NUVB stock with an $11.00 price target, though TipRanks' AI Analyst Spark rates it "Neutral" due to large losses despite revenue growth.
Nuvation Bio (NUVB) Jefferies Global Healthcare Conference 2026 Summary
Nuvation Bio (NUVB) presented at the Jefferies Global Healthcare Conference 2026, highlighting the strong performance of its drug IBTROZI, which leads the ROS1 market with high response rates and durable efficacy, benefiting from recent NCCN guideline changes. The company also discussed its pipeline, including safusidenib for IDH1 mutant glioma with data expected in 2027, and the ongoing TRUST-IV study for IBTROZI in earlier-stage disease. The presentation emphasized market growth driven by increased molecular testing and the long-term potential of their chronic disease therapies.
Nuvation Bio, Inc. Class A Actuals & Estimates (NYSE:NUVB)
This article provides an overview of Nuvation Bio Inc. (NYSE: NUVB) stock performance, financial estimates, and analyst forecasts. It covers key metrics like current stock price, historical highs and lows, market capitalization, volatility, and details on past and upcoming earnings reports, including revenue and net income figures.
Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes
Nuvation Bio Inc. has announced the pricing of an upsized underwritten offering of $250.0 million in 0.75% Convertible Senior Notes due in 2032. The net proceeds, estimated at approximately $241.2 million, will be used to pay for capped call transactions, repay a senior secured loan agreement, and for general corporate purposes. The offering includes an option for underwriters to purchase an additional $37.5 million in notes to cover over-allotments.
Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes
Nuvation Bio Inc. (NYSE: NUVB) announced the pricing of an upsized underwritten offering of $250.0 million in 0.75% Convertible Senior Notes due 2032, an increase from the initial $200.0 million. The company expects net proceeds of approximately $241.2 million, which will be used to fund capped call transactions, repay obligations under its senior secured loan agreement, and for general corporate purposes. The Notes will mature on July 1, 2032, and are convertible into cash, Class A common stock, or a combination thereof, with an initial conversion price of $7.84 per share.
Nuvation Bio Announces Proposed Convertible Senior Notes Offering
Nuvation Bio Inc. announced its intent to offer $200.0 million in Convertible Senior Notes due in 2032, with an option for underwriters to purchase an additional $30.0 million. The company plans to use the proceeds to cover capped call transactions, repay its senior secured loan, and for general corporate purposes. The offering is subject to market conditions, and the notes will be unsecured obligations, maturing on July 1, 2032.
Nuvation Bio’s chief people officer sells $753k in stock
Nuvation Bio's Chief People Officer, Markel Stacy, sold 125,000 shares of Class A Common Stock for $753,187, following the exercise of stock options. This sale was part of a pre-arranged trading plan, occurring after the company's stock surged 215% over the past year. Nuvation Bio also reported strong Q1 2026 earnings, announced a partnership with Thermo Fisher Scientific, and presented positive data from its TRUST-II study.
Nuvation Bio prices $250M convertible notes offering
Nuvation Bio Inc. has priced an upsized offering of $250 million in convertible senior notes due in 2032, increasing from a previously announced $200 million. The biotech company will use the proceeds to pay for capped call transactions, repay its existing senior secured loan of $217 million, and fund general corporate purposes. Despite being unprofitable, Nuvation Bio boasts significant revenue growth and strong liquidity.
Nuvation Bio CFO Sauvage sells $286k in stock
Nuvation Bio's CFO, Philippe Sauvage, sold 47,668 shares of Class A Common Stock for $286,370 on June 23, 2026, as part of a pre-arranged trading plan. This transaction occurred after he exercised stock options to acquire the shares. Following the sale, Sauvage holds 12,673 direct shares and 702,332 derivative securities in the company.
Nuvation Bio CFO Sauvage sells $286k in stock
Nuvation Bio's CFO, Philippe Sauvage, sold 47,668 shares of Class A Common Stock for $286,370 on June 23, 2026, after exercising stock options. This sale was pre-arranged under a 10b5-1 plan, and comes amidst the company's stock surging 215% over the past year, though an InvestingPro analysis suggests it might be overvalued. Nuvation Bio also recently reported strong Q1 2026 earnings and positive developments for its drug IBTROZI.
Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes
Nuvation Bio Inc. announced the pricing of an upsized underwritten offering of $250.0 million aggregate principal amount of 0.75% Convertible Senior Notes due in 2032, an increase from the previously announced $200.0 million. The company expects net proceeds of approximately $241.2 million, which will be used to pay for capped call transactions, repay its senior secured loan agreement, and for general corporate purposes. The notes will mature on July 1, 2032, and are convertible into cash, Class A common stock, or a combination thereof, at Nuvation Bio's election, with an initial conversion rate of 127.4941 shares per $1,000 principal amount.
Nuvation Bio stock tumbles on $200M convertible notes offering
Nuvation Bio Inc. (NYSE:NUVB) shares dropped 11.8% in premarket trading after the oncology company announced a plan to offer $200 million in convertible senior notes due 2032. The company will use the proceeds to pay for capped call transactions, repay existing senior secured loan obligations, and for general corporate purposes. Jefferies LLC, Citigroup, and Cantor Fitzgerald & Co. are serving as joint bookrunning managers for the offering.
Nuvation Bio CFO Sauvage sells $286k in stock By Investing.com
Nuvation Bio Inc.'s CFO, Philippe Sauvage, sold 47,668 shares of Class A Common Stock for $286,370 on June 23, 2026, as part of a pre-arranged trading plan, after exercising stock options. Despite a significant stock surge, InvestingPro suggests the shares might be overvalued. The company recently reported strong Q1 2026 earnings, completed a technology transfer for IBTROZI manufacturing, and received an "Outperform" rating from RBC Capital.
Nuvation Bio chief regulatory officer sells $379k in stock
Kerry Wentworth, Chief Regulatory Officer at Nuvation Bio Inc. (NASDAQ:NUVB), sold 63,000 shares of company stock worth $379,190 on June 23, 2026, following the exercise of stock options. This sale was conducted under a 10b5-1 trading plan and comes after a significant 215% surge in Nuvation Bio's stock over the past year. The transaction reduced Wentworth's direct holdings to 53,000 shares, while the company has recently reported strong first-quarter 2026 earnings and positive developments in its clinical trials and manufacturing.
Nuvation Bio chief regulatory officer sells $379k in stock
Kerry Wentworth, Chief Regulatory Officer at Nuvation Bio Inc. (NASDAQ:NUVB), sold 63,000 shares of the company’s Class A Common Stock for approximately $379,190 on June 23, 2026, following the exercise of stock options. The sale was executed via a 10b5-1 trading plan. This transaction occurred after Nuvation Bio's stock surged 215% over the past year, though InvestingPro suggests it may be overvalued relative to its Fair Value.
Nuvation Bio director Robert Mashal buys $118,250 in stock
Robert Mashal, a director at Nuvation Bio Inc. (NASDAQ:NUVB), recently purchased 25,000 shares of the company’s Class A Common Stock for $118,250 through his revocable trust. This transaction increases his indirect ownership to 225,000 shares. The purchase comes as InvestingPro analysis suggests the stock is undervalued, having delivered a 163% return over the past year.
Nuvation Bio director Robert Mashal buys $118,250 in stock
Nuvation Bio Inc. director Robert Mashal recently purchased 25,000 shares of the company's Class A Common Stock for $118,250, increasing his indirect ownership to 225,000 shares. This transaction occurred amidst positive news for Nuvation Bio, including strong Q1 2026 earnings, a manufacturing partnership with Thermo Fisher Scientific for IBTROZI, and promising patient-reported outcomes from the TRUST-II study. RBC Capital has reiterated an Outperform rating with a $20.00 price target, highlighting the continued value in the ROS1 market.
Nuvation Bio (NUVB) director’s trust buys 25,000 Class A shares
Nuvation Bio director Robert Mashal, through his revocable trust, purchased 25,000 shares of Class A Common Stock at $4.73 per share in an open-market transaction. This acquisition increases the trust's total holdings to 225,000 shares of Nuvation Bio Class A Common Stock. The transaction is detailed in a Form 4 SEC filing, indicating a positive sentiment for the company.
Nuvation Bio (NUVB) shareholders elect directors, ratify KPMG and approve pay
Nuvation Bio Inc. (NUVB) announced the results of its 2026 Annual Meeting. Shareholders elected Class A directors Robert B. Bazemore, Jr. and Robert Mashal, M.D., and Class B director Kim Blickenstaff, to serve until the 2029 annual meeting. Additionally, KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026, and executive compensation was approved on an advisory basis.
Nuvation Bio Inc. Files Form 8-K with SEC Detailing Company Information and Annual Meeting Results
Nuvation Bio Inc. filed an 8-K form with the SEC, detailing the results of its 2026 Annual Meeting of Stockholders held on May 21, 2026. Key outcomes included the election of directors, ratification of KPMG LLP as auditor, and an advisory vote on executive compensation. The report also noted the company's transition out of "emerging growth company" status.
Nuvation Bio Inc. (NUVB) director awarded 76,923 stock options in corrected filing
Nuvation Bio Inc. director Xiangmin Cui's insider trading report has been corrected through an amended Form 4 filing, revealing he was granted 76,923 stock options for Class A common stock on February 27, 2026. This rectifies an administrative error in a previous filing that reported 74,813 options. The options have an exercise price of $5.91 and vest over 24 months, starting January 1, 2026.
Nuvation Bio (NUVB) director Cui receives 123,397 stock options expiring 2036
Nuvation Bio (NUVB) director Xiangmin Cui was granted 123,397 stock options with an exercise price of $4.79 per share, expiring on May 20, 2036. These options represent a compensation-related acquisition and will fully vest on the earlier of May 21, 2026, or the next shareholder annual meeting, contingent on Cui's continuous service. This transaction increases Cui's derivative holdings in the company.
Nuvation Bio (NUVB) director gets 123,397 stock options at $4.79
Nuvation Bio Inc. director Robert B. Bazemore was granted 123,397 stock options for Class A common stock with an exercise price of $4.79 per share, expiring on May 20, 2036. The options will vest 100% on May 21, 2026, or the next annual shareholder meeting, contingent on his continuous service. This transaction is a compensation-related award and does not involve open-market purchases or sales.
Director at Nuvation Bio (NASDAQ: NUVB) awarded 123,397 stock options
Robert Mashal, a director at Nuvation Bio (NASDAQ: NUVB), was granted 123,397 stock options with an exercise price of $4.79 per share. These options will vest 100% on the earlier of May 21, 2026, or the next shareholder annual meeting, provided he maintains continuous service. The options are set to expire on May 20, 2036.
Nuvation Bio to Present New Quality-of-Life Data for IBTROZI® (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting
Nuvation Bio will present new patient-reported outcomes data from the pivotal TRUST-II study of IBTROZI® (taletrectinib) at the ASCO 2026 Annual Meeting. The data shows that 88% of patients with ROS1-positive non-small cell lung cancer (NSCLC) reported improved or stable quality of life, with sustained benefits and preservation of cognitive function. IBTROZI also provided rapid and durable relief from symptoms like cough and shortness of breath in both TKI-naïve and pretreated patients.
Nuvation Bio (NUVB) Proxy filing Summary
Nuvation Bio (NUVB) has scheduled its Annual Meeting for May 21, 2026, where stockholders will vote on electing three directors, ratifying KPMG LLP as the auditor for 2026, and an advisory vote on executive compensation. The board recommends voting in favor of all proposals. The article outlines the voting process, board composition, and corporate governance details.
Nuvation Bio (NYSE:NUVB) - Stock Analysis
Nuvation Bio (NYSE:NUVB) is a clinical-stage biopharmaceutical company focused on cancer treatment. The company recently reported a surprise statutory profit in Q1 2026, exceeding analyst expectations, and its lead product candidate, IBTROZI (taletrectinib), has received FDA approval and endorsements for ROS1-positive non-small cell lung cancer (NSCLC). Despite positive clinical developments and analyst upgrades, the company faces a shareholder investigation into corporate actions and competitive risks in the oncology market.
Results: Nuvation Bio Inc. Confounded Analyst Expectations With A Surprise Profit
Nuvation Bio Inc. (NYSE: NUVB) shares rose 8.1% after reporting a surprise profit of US$0.01 per share and revenues of US$83m for the first quarter, significantly exceeding analyst expectations. Analysts have increased their price target to US$12.33 and reduced their loss per share forecasts, reflecting increased optimism despite projected revenue growth slowing from historical rates. The company is expected to grow faster than the wider industry.
Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update
Nuvation Bio reported strong financial results for the first quarter of 2026, with IBTROZI® (taletrectinib) generating $18.5 million in net product revenues and continuing to show impressive durability in ROS1+ NSCLC patients. The company also secured global rights to safusidenib for IDH1-mutant glioma and made progress with its drug-drug conjugate platform. Nuvation Bio ended the quarter with a strong balance sheet of $533.7 million in cash, cash equivalents, and marketable securities.
Eisai deal lifts Nuvation Bio (NYSE: NUVB) to Q1 2026 profit
Nuvation Bio (NYSE: NUVB) reported a strong Q1 2026, achieving a net income of $5.4 million, a significant turnaround from a $53.2 million net loss the previous year. This profitability was driven by a surge in total revenue to $83.2 million, largely attributed to initial U.S. sales of IBTROZI and a substantial upfront payment from an Eisai collaboration and license agreement. The company ended the quarter with a robust cash position of $533.7 million, supporting its ongoing pipeline advancements.
Nuvation Bio Inc. (NUVB) Lags Q1 Earnings Estimates
Nuvation Bio Inc. (NUVB) reported Q1 earnings of $0.01 per share, significantly missing the Zacks Consensus Estimate of $0.12, though this was an improvement from a loss of $0.16 per share a year ago. The company's revenue of $83.23 million for the quarter ended March 2026 surpassed consensus estimates by 0.36%, a substantial increase from $3.08 million in the prior year. Despite revenue beats, NUVB shares have declined by 49.9% year-to-date, with the stock currently holding a Zacks Rank #3 (Hold).
Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update
Nuvation Bio reported strong first-quarter 2026 financial results, with IBTROZI® generating $18.5 million in net product revenues and demonstrating impressive durability in advanced ROS1-positive NSCLC patients. The company also secured global rights for safusidenib, an IDH1-mutant glioma treatment, and plans to advance its Phase 3 SIGMA study. Nuvation Bio achieved a net income of $5.4 million for the quarter, a significant improvement from the prior year's loss.
Nuvation Bio chief regulatory officer sells $184,279 in stock
Kerry Wentworth, Chief Regulatory Officer at Nuvation Bio Inc. (NASDAQ:NUVB), sold 36,750 shares of the company’s Class A Common Stock for $184,279 after exercising stock options. This transaction follows a significant 158.59% return in Nuvation Bio shares over the past year, with the stock deemed undervalued by InvestingPro analysis. The company has also reported recent developments including an amended license agreement for safusidenib and the European Medicines Agency's validation of a Marketing Authorization Application for taletrectinib, alongside positive analyst ratings.
Nuvation Bio Inc (NUVB): Take a Look at Glioma Revenue Potential
RBC Capital analysts have increased their price target for Nuvation Bio Inc (NUVB) to $20, reiterating an Overweight rating due to the significant revenue potential of its glioma drug candidate, safusidenib. The drug is currently in Phase 3 trials, with recent protocol updates reflecting alignment with US regulators and potential for swift approval in an underserved market. RBC Capital estimates safusidenib could generate up to $3.4 billion in US sales, addressing a critical unmet need in both high-grade and low-grade glioma treatment.
Nuvation Bio chief regulatory officer sells $184,279 in stock By Investing.com
Nuvation Bio's Chief Regulatory Officer, Kerry Wentworth, sold 36,750 shares of Class A Common Stock for $184,279 after exercising stock options. This transaction follows Nuvation Bio's shares delivering a 158.59% return over the past year, with the stock appearing undervalued according to InvestingPro. The company has also recently announced an amended license agreement for safusidenib and the European Medicines Agency's validation of taletrectinib's Marketing Authorization Application, leading to positive analyst revisions.
/U P D A T E -- Nuvation Bio Inc./
Nuvation Bio Inc. announced updated long-term follow-up data from its pivotal TRUST-I and TRUST-II trials for IBTROZI® (taletrectinib) in patients with advanced ROS1-positive non-small cell lung cancer. The data presented at AACR 2026 demonstrated highly durable responses, with a median duration of response of nearly 50 months and a median progression-free survival of 46.1 months in TKI-naïve patients, alongside robust intracranial activity and a manageable safety profile. IBTROZI is approved in the U.S., Japan, and China for ROS1+ NSCLC, and its Marketing Authorisation Application has been accepted for review by the European Medicines Agency.
Nuvation Bio chief regulatory officer sells $184,279 in stock By Investing.com
Nuvation Bio's Chief Regulatory Officer, Kerry Wentworth, sold 36,750 shares of Class A Common Stock for $184,279 after exercising stock options. The sale was executed under a pre-arranged 10b5-1 plan. This transaction follows a significant 158.59% return for Nuvation Bio shares over the past year, and the company has recently made important strides with an amended license agreement for safusidenib and the European Medicines Agency's validation of taletrectinib.
Nuvation Bio chief regulatory officer sells $184,279 in stock
Kerry Wentworth, Chief Regulatory Officer at Nuvation Bio Inc. (NASDAQ:NUVB), sold 36,750 shares worth $184,279 after exercising stock options. This transaction follows Nuvation Bio's significant year-long performance and comes amidst positive analyst outlooks and strategic developments, including a new license agreement for safusidenib and regulatory validation for taletrectinib.
[144] Nuvation Bio Inc. SEC Filing
This SEC filing (Form 144) details the proposed sale of 50,000 shares of Nuvation Bio Inc. common stock, valued at $240,500.00, acquired through the exercise of stock options on April 17, 2026. The sale is to be conducted via Morgan Stanley Smith Barney LLC on the NYSE. The document confirms that no material adverse non-public information is known by the seller.
Nuvation Bio Inc. (NUVB) and Eisai Get EMA Validation for Taletrectinib
Nuvation Bio Inc. and Eisai have received EMA validation for their Marketing Authorisation Application for Taletrectinib, a treatment for advanced ROS1-positive non-small cell lung cancer. This approval follows an earlier licensing deal and targets a significant patient population in Europe. Taletrectinib is positioned as a potential standard-of-care due to its strong efficacy and safety profile.
